Manufactures specialty chemicals and pharmaceutical intermediates for global pharmaceutical customers across three verticals. The contrast media vertical supplies gadolinium and iodinated contrast media intermediates to formulation customers; FY26 revenue grew 23% YoY on new product launches, with Q4 alone surging 91% YoY to INR 193 crore. PI/API revenue fell 35% YoY to INR 298 crore as customers worked through inventory, but management says destocking is complete and FY27 should exceed the FY25 peak of ~INR 460 crore. A third vertical in high-intensity sweeteners is under validation, with trial shipments expected over coming quarters. Manufacturing runs from Ambernath and Mahad; Mahad Unit 3 backward integration for a contrast media raw material begins production in H2 FY27 to improve margins via supply chain self-reliance. New capacity at Vizag (a multi-year greenfield project) and a peptide-focused R&D centre in Hyderabad are being added; raw materials account for 41% of revenue and the company closed FY26 debt-free with INR 400 crore in liquid assets. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Contrast media intermediates, Pharmaceutical Intermediates / APIs and CDMO, High-intensity sweeteners. Specialty chemicals and pharmaceutical intermediates; investment-heavy expansion phase with multiple greenfield and R&D projects
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 712 | 1,030 | 947 |
| EBITDA (ex other income) | 219 | 378 | 294 |
| margin % | 30.8 | 36.7 | 31.0 |
| Owners' profit | 164 | 305 | 248 |
| EPS, as reported (₹) | 9.44 | 17.59 | 14.29 |
| ROE % · ROCE % | 19.4 · 25.8 | 26.9 · 35.0 | 18.2 · 24.0 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 |
| Cash from operations | 241 | 46 | 334 |
| Capex | (173) | (80) | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Profit before tax | 77 | 132 | 147 | 123 | 69 | 54 | 87 | 106 |
| Net profit | 58 | 99 | 110 | 91 | 52 | 40 | 64 | 78 |
| EPS (₹) | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 19 Aug 2026 · Intimation of 58th AGM newspaper publication and e-voting details | compliance | minimal | — | — |
| 18 Aug 2026 · Blue Jet Healthcare files BRSR for FY26 with TUV India assurance | compliance | medium | — | — |
| 18 Aug 2026 · AGM Sept 21, 2026: Dividend Rs 1.20, Director and Auditor Re-appointments | board shareholder meetings | low | — | — |
| 12 Aug 2026 · Blue Jet Healthcare files 58th AGM newspaper notice | compliance | minimal | — | — |
| 7 Aug 2026 · Blue Jet Healthcare Q1 FY27 earnings call transcript filed | investor communications | medium | — | — |
| 4 Aug 2026 · Blue Jet Healthcare publishes Q1 FY27 unaudited results in newspapers | compliance | minimal | — | — |
| 3 Aug 2026 · Audio recording of Q1 FY27 earnings call submitted to exchanges | investor communications | low | — | — |
| 3 Aug 2026 · Blue Jet Q1FY27: Revenue up 25% QoQ, EBITDA margin expands to 33.5% | investor communications | medium | — | — |
| 3 Aug 2026 · Q1 FY27 results dip YoY; dividend, director and auditor re-appointments approved | results | high | — | — |
| 3 Aug 2026 · Q1 FY27 results show revenue dip; Rs 1.2 dividend, Rs 800 cr QIP raise | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 42.1 | 28.9 | 116 of 169 | 32% |
| P/B | 7.3 | 3.3 | 137 of 163 | 16% |
| ROCE | 23.5 | 10.8 | 19 of 183 | 90% |
| ROE | 18.2 | 10.4 | 29 of 171 | 84% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 38.7 | 17.5 | 11 of 165 | 94% |
| Revenue growth | (17.4) | 16.3 | 138 of 161 | 14% |
| Profit growth | (14.2) | 30.9 | 115 of 158 | 27% |
| Market cap | 9887 | 839 | 44 of 182 | 76% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
